$ADIL News

Adial Pharmaceuticals Reports 2026 First Quarter Financial Results and Provides Business Update

Adial Pharmaceuticals Q1 EPS $(1.48) Beats $(2.73) Estimate

Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045

Adial Pharmaceuticals Submits Application to FDA Commissioner’s National Priority Voucher (CNPV) Pilot Program for AD04 Clinical Development Program

Adial Pharmaceuticals Submits Application For FDA's Priority Voucher Pilot Program For AD04 Clinical Development

Adial Pharmaceuticals Successfully Completes Manufacturing of Demonstration Batch Production, Enabling Clinical and Registration Production for AD04 Planned Phase 3 Trial

EXCLUSIVE: Adial Pharmaceuticals Clears Manufacturing Milestone Ahead Of Pivotal Study For Alcohol Use Disorder Drug

EXCLUSIVE: Adial Reaches Key Milestone In Demonstration Batch Production For AD04 Ahead Of Phase 3 Trials

Adial Pharmaceuticals Commends Congress on Introduction of Bipartisan Legislation Expanding Access to Emerging AUD Therapies for Veterans

Adial Pharmaceuticals Lead Drug Fits New Policy Mood As Bipartisan Bill Signals Broader Lens On Alcohol Use Disorder

Adial Pharmaceuticals Reports 2025 Fiscal Year Financial Results and Provides Business Update

Adial Pharmaceuticals Q4 EPS $(11.48) Misses $(0.09) Estimate

12 Health Care Stocks Moving In Wednesday's Intraday Session

Adial Pharmaceuticals Signs an Exclusive AD04 Collaboration Framework with Molteni Farmaceutici for Europe which Anticipates Nearly $60 Million in Potential Royalties and Milestones upon execution of a Definitive Agreement

EXCLUSIVE: Adial Pharma Eyes Europe Deal For Lead Drug For Alcohol Use Disrder Worth Up To $60 Million

EXCLUSIVE: Adial Pharmaceuticals Signs Exclusive AD04 Agreement With Molteni Farmaceutici For Europe; Deal Anticipates Nearly $60M Potential Royalties, Milestones

Adial Pharmaceuticals Regains Full Compliance with Nasdaq Listing Requirement

Adial Pharmaceuticals Regains Nasdaq Compliance

Adial Pharmaceuticals Highlights FDA Policy Direction That May Reduce Pivotal Trial Burden from Two Studies to One

Adial Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference